Martin Gliem1,2, Johannes Birtel1,2, Philipp Herrmann1,2, Rolf Fimmers3, Moritz Berger3, Christoph Coch4, Almut Wingen4, Frank G Holz1,2, Peter Charbel Issa5. 1. Department of Ophthalmology, University Hospital of Bonn, Bonn, Germany. 2. Centre for Rare Diseases Bonn (ZSEB), University of Bonn, Bonn, Germany. 3. Institute of Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, Germany. 4. Study Center Bonn, Institute of Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn, Bonn, Germany. 5. Oxford Eye Hospital, Oxford University Hospitals NHS Foundation Trust, and Nuffield Laboratory of Ophthalmology, Department of Clinical Neurosciences, University of Oxford, Oxford, UK. study-enquiry@outlook.com.
Abstract
PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE). METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life. RESULTS: BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications. CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.
PURPOSE: To evaluate the use of 2 mg intravitreal aflibercept for treatment of choroidal neovascularization (CNV) secondary to angioid streaks in patients with pseudoxanthoma elasticum (PXE). METHODS: In this 12-month prospective, open-label, uncontrolled, non-randomized interventional clinical trial, 15 PXE patients with CNV (mean age: 53 years, range 22-65) received one initial intravitreal injection of 2 mg aflibercept. Further injections were based on CNV activity at monthly examinations. The primary endpoint was change of best corrected visual acuity (BCVA) after 12 months. Secondary outcomes were change of central retinal thickness (CRT), leakage from CNV, retinal sensitivity, and vision-related quality of life. RESULTS:BCVA improved from 75.0 ± 10.8 (± SD, Snellen equivalent 20/32) to 79.3 ± 7.3 ETDRS letters (20/32) at final visit (p = 0.083). CRT decreased from 317 ± 81 to 279 ± 51 μm (p = 0.004). Retinal sensitivity on microperimetry changed from 17.8 ± 4.5 to 18.5 ± 4.3 dB (p = 0.103) and vision-related quality of life from a VQF-25 score of 80.7 ± 10.4 to 83.5 ± 14.5 (p = 0.554). The mean number of injections was 6.7 ± 2.6, and 5 participants had persistent or reactivated CNV activity at final visit. The observed adverse events were comparable with studies on aflibercept for other indications. CONCLUSION: The results of this study indicate that intravitreal aflibercept is a treatment option for CNV secondary to PXE.
Authors: Peter Charbel Issa; Robert P Finger; Frank G Holz; Hendrik P N Scholl Journal: Invest Ophthalmol Vis Sci Date: 2009-06-24 Impact factor: 4.799
Authors: Quan Dong Nguyen; Syed Mahmood Shah; Gulnar Hafiz; Edward Quinlan; Jennifer Sung; Karen Chu; Jesse M Cedarbaum; Peter A Campochiaro Journal: Ophthalmology Date: 2006-07-28 Impact factor: 12.079
Authors: Jocelyn Holash; Sam Davis; Nick Papadopoulos; Susan D Croll; Lillian Ho; Michelle Russell; Patricia Boland; Ray Leidich; Donna Hylton; Elena Burova; Ella Ioffe; Tammy Huang; Czeslaw Radziejewski; Kevin Bailey; James P Fandl; Tom Daly; Stanley J Wiegand; George D Yancopoulos; John S Rudge Journal: Proc Natl Acad Sci U S A Date: 2002-08-12 Impact factor: 11.205
Authors: Robert S Jansen; Suzanne Duijst; Sunny Mahakena; Daniela Sommer; Flóra Szeri; András Váradi; Astrid Plomp; Arthur A Bergen; Ronald P J Oude Elferink; Piet Borst; Koen van de Wetering Journal: Arterioscler Thromb Vasc Biol Date: 2014-06-26 Impact factor: 8.311
Authors: Martin Gliem; Philipp L Müller; Johannes Birtel; Doris Hendig; Frank G Holz; Peter Charbel Issa Journal: Invest Ophthalmol Vis Sci Date: 2016-06-01 Impact factor: 4.799
Authors: Robert S Jansen; Aslı Küçükosmanoglu; Marcel de Haas; Sunny Sapthu; Jon Andoni Otero; Ilse E M Hegman; Arthur A B Bergen; Theo G M F Gorgels; P Borst; Koen van de Wetering Journal: Proc Natl Acad Sci U S A Date: 2013-11-25 Impact factor: 11.205
Authors: Martin Gliem; Johannes Birtel; Philipp L Müller; Doris Hendig; Isabel Faust; Philipp Herrmann; Frank G Holz; Grazyna Adamus; Peter Charbel Issa Journal: JAMA Ophthalmol Date: 2019-10-01 Impact factor: 7.389
Authors: Martin Gliem; Julie De Zaeytijd; Robert P Finger; Frank G Holz; Bart P Leroy; Peter Charbel Issa Journal: Front Genet Date: 2013-04-04 Impact factor: 4.599
Authors: Sónia Torres-Costa; João Bernardes; Sofia Sousa Mano; Joana Medeiros-Pinto; Ana Carolina Abreu; Maria João Furtado; Rufino Silva; Carlos Marques-Neves; Fernando Falcão-Reis; Ângela Carneiro; Luísa Colaço; Manuel Falcão Journal: J Ophthalmol Date: 2022-07-09 Impact factor: 1.974